BACKGROUND: The accurate diagnosis of idiopathic pulmonary fibrosis (IPF) is a major clinical challenge. We developed a model to diagnose IPF by applying Bayesian probit regression (BPR) modelling to gene expression profiles of whole lung tissue. METHODS: Whole lung tissue was obtained from patients with idiopathic pulmonary fibrosis (IPF) undergoing surgical lung biopsy or lung transplantation. Controls were obtained from normal organ donors. We performed cluster analyses to explore differences in our dataset. No significant difference was found between samples obtained from different lobes of the same patient. A significant difference was found between samples obtained at biopsy versus explant. Following preliminary analysis of the complete dataset, we selected three subsets for the development of diagnostic gene signatures: the first signature was developed from all IPF samples (as compared to controls); the second signature was developed from the subset of IPF samples obtained at biopsy; the third signature was developed from IPF explants. To assess the validity of each signature, we used an independent cohort of IPF and normal samples. Each signature was used to predict phenotype (IPF versus normal) in samples from the validation cohort. We compared the models' predictions to the true phenotype of each validation sample, and then calculated sensitivity, specificity and accuracy. RESULTS: Surprisingly, we found that all three signatures were reasonably valid predictors of diagnosis, with small differences in test sensitivity, specificity and overall accuracy. CONCLUSIONS: This study represents the first use of BPR on whole lung tissue; previously, BPR was primarily used to develop predictive models for cancer. This also represents the first report of an independently validated IPF gene expression signature. In summary, BPR is a promising tool for the development of gene expression signatures from non-neoplastic lung tissue. In the future, BPR might be used to develop definitive diagnostic gene signatures for IPF, prognostic gene signatures for IPF or gene signatures for other non-neoplastic lung disorders such as bronchiolitis obliterans.
BACKGROUND: The accurate diagnosis of idiopathic pulmonary fibrosis (IPF) is a major clinical challenge. We developed a model to diagnose IPF by applying Bayesian probit regression (BPR) modelling to gene expression profiles of whole lung tissue. METHODS: Whole lung tissue was obtained from patients with idiopathic pulmonary fibrosis (IPF) undergoing surgical lung biopsy or lung transplantation. Controls were obtained from normal organ donors. We performed cluster analyses to explore differences in our dataset. No significant difference was found between samples obtained from different lobes of the same patient. A significant difference was found between samples obtained at biopsy versus explant. Following preliminary analysis of the complete dataset, we selected three subsets for the development of diagnostic gene signatures: the first signature was developed from all IPF samples (as compared to controls); the second signature was developed from the subset of IPF samples obtained at biopsy; the third signature was developed from IPF explants. To assess the validity of each signature, we used an independent cohort of IPF and normal samples. Each signature was used to predict phenotype (IPF versus normal) in samples from the validation cohort. We compared the models' predictions to the true phenotype of each validation sample, and then calculated sensitivity, specificity and accuracy. RESULTS: Surprisingly, we found that all three signatures were reasonably valid predictors of diagnosis, with small differences in test sensitivity, specificity and overall accuracy. CONCLUSIONS: This study represents the first use of BPR on whole lung tissue; previously, BPR was primarily used to develop predictive models for cancer. This also represents the first report of an independently validated IPF gene expression signature. In summary, BPR is a promising tool for the development of gene expression signatures from non-neoplastic lung tissue. In the future, BPR might be used to develop definitive diagnostic gene signatures for IPF, prognostic gene signatures for IPF or gene signatures for other non-neoplastic lung disorders such as bronchiolitis obliterans.
Authors: Kevin R Flaherty; Adin-Cristian Andrei; Talmadge E King; Ganesh Raghu; Thomas V Colby; Athol Wells; Nadir Bassily; Kevin Brown; Roland du Bois; Andrew Flint; Steven E Gay; Barry H Gross; Ella A Kazerooni; Robert Knapp; Edmund Louvar; David Lynch; Andrew G Nicholson; John Quick; Victor J Thannickal; William D Travis; James Vyskocil; Frazer A Wadenstorer; Jeffrey Wilt; Galen B Toews; Susan Murray; Fernando J Martinez Journal: Am J Respir Crit Care Med Date: 2007-01-25 Impact factor: 21.405
Authors: M Thomeer; M Demedts; J Behr; R Buhl; U Costabel; C D R Flower; J Verschakelen; F Laurent; A G Nicholson; E K Verbeken; F Capron; M Sardina; G Corvasce; I Lankhorst Journal: Eur Respir J Date: 2007-12-05 Impact factor: 16.671
Authors: Amy L Olson; Jeffrey J Swigris; Dennis C Lezotte; Jill M Norris; Carla G Wilson; Kevin K Brown Journal: Am J Respir Crit Care Med Date: 2007-05-03 Impact factor: 21.405
Authors: William D Travis; Gary Hunninghake; Talmadge E King; David A Lynch; Thomas V Colby; Jeffrey R Galvin; Kevin K Brown; Man Pyo Chung; Jean-François Cordier; Roland M du Bois; Kevin R Flaherty; Teri J Franks; David M Hansell; Thomas E Hartman; Ella A Kazerooni; Dong Soon Kim; Masanori Kitaichi; Takashi Koyama; Fernando J Martinez; Sonoko Nagai; David E Midthun; Nestor L Müller; Andrew G Nicholson; Ganesh Raghu; Moisés Selman; Athol Wells Journal: Am J Respir Crit Care Med Date: 2008-04-03 Impact factor: 21.405
Authors: Prateek Mendiratta; Elahe Mostaghel; Justin Guinney; Alok K Tewari; Alessandro Porrello; William T Barry; Peter S Nelson; Phillip G Febbo Journal: J Clin Oncol Date: 2009-03-16 Impact factor: 44.544
Authors: Andrew Berchuck; Edwin S Iversen; Jingqin Luo; Jennifer P Clarke; Hisani Horne; Douglas A Levine; Jeff Boyd; Miguel A Alonso; Angeles Alvarez Secord; Marcus Q Bernardini; Jason C Barnett; Todd Boren; Susan K Murphy; Holly K Dressman; Jeffrey R Marks; Johnathan M Lancaster Journal: Clin Cancer Res Date: 2009-03-24 Impact factor: 12.531
Authors: Ivan O Rosas; Thomas J Richards; Kazuhisa Konishi; Yingze Zhang; Kevin Gibson; Anna E Lokshin; Kathleen O Lindell; Jose Cisneros; Sandra D Macdonald; Annie Pardo; Frank Sciurba; James Dauber; Moises Selman; Bernadette R Gochuico; Naftali Kaminski Journal: PLoS Med Date: 2008-04-29 Impact factor: 11.069
Authors: Kathy Boon; Nathaniel W Bailey; Jun Yang; Mark P Steel; Steve Groshong; Dolly Kervitsky; Kevin K Brown; Marvin I Schwarz; David A Schwartz Journal: PLoS One Date: 2009-04-06 Impact factor: 3.240
Authors: Taku Nakashima; Tianju Liu; Biao Hu; Zhe Wu; Matthew Ullenbruch; Keitaro Omori; Lin Ding; Noboru Hattori; Sem H Phan Journal: Am J Respir Crit Care Med Date: 2019-10-15 Impact factor: 21.405
Authors: Fernando J Martinez; Alison Chisholm; Harold R Collard; Kevin R Flaherty; Jeffrey Myers; Ganesh Raghu; Simon L F Walsh; Eric S White; Luca Richeldi Journal: Lancet Respir Med Date: 2016-12-06 Impact factor: 30.700